India’s Koanna gets UK’s MHRA OK for Imatinib tablets

Koanna Healthcare UK, the subsidiary of Shilpa Mediacare India has received marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (UK MHRA) for the Imatinib tablets in multiple strengths of 100 mg and 400 mg.

Shilpa noted in a stock exchange filling on Wednesday that the marketing authorization application for this generic product is made through decentralized procedure in 15 EU member states, which involves major European countries like UK, Germany, Netherlands, France, Czech Republic, Belgium, Ireland, Romania etc.

Furthermore, out of 15 member states the first approval is received from UK MHRA.
Shilpa said that approvals from remaining member states will follow.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s